Cargando…
Boosting the diagnostic power of amyloid-β PET using a data-driven spatially informed classifier for decision support
BACKGROUND: Amyloid-β (Aβ) PET has emerged as clinically useful for more accurate diagnosis of patients with cognitive decline. Aβ deposition is a necessary cause or response to the cellular pathology of Alzheimer’s disease (AD). Usual clinical and research interpretation of amyloid PET does not ful...
Autores principales: | Venkataraman, Ashwin V., Bai, Wenjia, Whittington, Alex, Myers, James F., Rabiner, Eugenii A., Lingford-Hughes, Anne, Matthews, Paul M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582159/ https://www.ncbi.nlm.nih.gov/pubmed/34758867 http://dx.doi.org/10.1186/s13195-021-00910-8 |
Ejemplares similares
-
Relationship between astrocyte reactivity, using novel (11)C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals
por: Livingston, Nicholas R., et al.
Publicado: (2022) -
Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using (11)C-BU99008 PET and its relationship with amyloid load
por: Calsolaro, Valeria, et al.
Publicado: (2021) -
First evaluation of PET-based human biodistribution and radiation dosimetry of (11)C-BU99008, a tracer for imaging the imidazoline(2) binding site
por: Venkataraman, Ashwin V., et al.
Publicado: (2018) -
Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals
por: Turton, Samuel, et al.
Publicado: (2018) -
Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases
por: Wilson, Heather, et al.
Publicado: (2020)